Dr. Denise Scots-Knight
CEO and Co-Founder
Denise is our CEO, a board member and co-founder of Mereo. Denise has over 25 years’ experience in the biopharmaceutical industry both in R&D management and as a venture capitalist.
She started her career in R&D management at Amersham and Fisons and as a senior executive at Scientific Generics before joining Rothschild Asset Management as an investment manager. In 1999 she joined Nomura and became Managing Director after heading the life science investment team investing globally in biotechnology companies. She led the Phase4 Partners MBO from Nomura in 2010.
Denise had served on many US and European private and public boards including Idenix (until acquired by Merck for $3.85bn). She is currently a board member of Elanco Animal Health Incorporated (NYSE: ELAN) . Denise has a PhD and BSc (Hons) from Birmingham University and was a Fulbright scholar at UC Berkeley.
Richard is our CFO and a board member of Mereo. Richard joins from Shield Therapeutics plc where he has been Chief Financial Officer and Company Secretary. He was initially appointed as a Non-Executive Director at Shield in 2010 before moving to his current position in 2011 where he had a leading role establishing the finance operations and guiding Shield through its recent IPO. Prior to this, Richard had a career in investment banking, holding senior positions at Investec and Brewin Dolphin Securities, where he advised healthcare clients on a wide range of transactions and fundraisings including IPOs, M&A and fundraisings. Richard qualified as a Chartered Accountant with PwC in 1991.
GC and Co-Founder
Charles is our General Counsel, Company Secretary and a co-founder of Mereo.
He has over 20 years’ experience in corporate law and biopharmaceuticals.
He started his career as a corporate lawyer at Freshfields before joining Nomura as an Associate Director in 1998 where he worked for Nomura’s life science investment team investing globally in biotechnology companies.
Charles was part of Phase4 Partners’ MBO from Nomura in 2010.
Charles has an LLB (Hons) from Hull University.
Dr. Alastair MacKinnon
CMO and Co-Founder
Alastair is our Chief Medical Officer and a co-founder of Mereo. Prior to Mereo, he was a Partner at for Phase4 Partners, a global life science venture capital firm. He was also involved in Phase4’s MBO in 2010 having originally joined Nomura in 2005.
Before Nomura, he was a practising physician in the UK for 10 years. Alastair received a BSc and MBBS from King’s College London, is a Member of the Royal College of Surgeons of Edinburgh (MRCS) and has a Diploma in Corporate Finance from the London Business School. Alastair is a board member of Phase4 Partners.
Head of Corporate Development and Co-Founder
John is our Head of Corporate Development and a co-founder of Mereo. Prior to Mereo, he worked with the co-founders at Nomura then Phase4 Partners since 2000.
He has significant corporate, operational and transactional experience, having served in various executive, director and advisory roles throughout his career. He is a board member of Vaxart, Phase4 Partners, QUE Oncology and Catalyst Biosciences.
Previously, he was Executive VP Business Development at SEQUUS, where he was responsible for negotiating SEQUUS’ acquisition by ALZA. John also headed business development for VIVUS and Genome Therapeutics; where he established numerous alliances.
John holds a MBA from Harvard Business School and BS from Stanford University.
Head of Patient Access & Commercial Planning
Wills Hughes-Wilson is Head of Patient Access & Commercial Planning at Mereo and joined the team in March 2018. She has responsibility for leading and optimising the company’s patient access and commercialisation strategies.
Prior to joining Mereo, Wills was Chief Patient Access Officer and SVP Patient Access & External Affairs at Sobi, with executive accountability for Sobi’s go-to-market approach across a broad orphan drug portfolio. This included leading the global pricing, reimbursement and access teams, notably for the company’s successful first-in-class haemophilia product launches. Previous to that, she was Vice President Health & Market Access Policy at Genzyme.
Wills has been an active participant in the field of rare diseases and orphan drugs since the early 2000s, spanning membership of the EMA’s COMP WGIP Working Group, the European Commission’s EU Committee of Experts on Rare Diseases (EUCERD) and, currently, the Steering Group of the European Mechanism of Coordinated Access (MoCA).
Wills has a Bachelor’s Degree in Law and Politics (Hons) from Durham University.